Delayed Nasdaq 10:49:19 2024-04-24 am EDT 5-day change 1st Jan Change
3.31 USD +4.09% Intraday chart for LENSAR, Inc. +8.17% -5.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : LENSAR, Inc., Q4 2023 Earnings Call, Mar 04, 2024
LENSAR, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
LENSAR, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (LNSR) LENSAR Posts Q4 Revenue $12.1M MT
Top Premarket Gainers MT
Transcript : LENSAR, Inc., Q3 2023 Earnings Call, Nov 09, 2023
LENSAR, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (LNSR) LENSAR Reports Q3 Revenue $9.8M MT
LENSAR, Inc. Announces Retirement of John P. McLaughlin from the Board, Effective October 31, 2023 CI
Transcript : LENSAR, Inc., Q2 2023 Earnings Call, Aug 09, 2023
LENSAR, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (LNSR) LENSAR Reports Q2 Revenue $12M MT
Lensar, Inc. Reports Adoption of Ally System in Multi-Center Ophthalmology Groups CI
LENSAR, Inc.(NasdaqCM:LNSR) added to Russell Microcap Value Index CI
LENSAR, Inc.(NasdaqCM:LNSR) added to Russell 3000E Value Index CI
LENSAR, Inc. announced that it has received $20 million in funding from NR-GRI Partners, LP CI
Transcript : LENSAR, Inc., Q1 2023 Earnings Call, May 15, 2023
Earnings Flash (LNSR) LENSAR Reports Q1 Revenue $8.3M, vs. Street Est of $9.1M MT
LENSAR, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
LENSAR, Inc. announced that it expects to receive $20 million in funding from NR-GRI Partners, LP CI
Earnings Flash (LNSR) LENSAR Reports Q4 Revenue $10.2M, vs. Street Est of $10M MT
LENSAR, Inc. Provides Revenue Guidance for the Fiscal 2023 CI
Transcript : LENSAR, Inc., Q4 2022 Earnings Call, Mar 16, 2023
LENSAR, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
LENSAR, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Chart LENSAR, Inc.
More charts
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.18 USD
Average target price
8 USD
Spread / Average Target
+151.57%
Consensus
  1. Stock Market
  2. Equities
  3. LNSR Stock
  4. News LENSAR, Inc.
  5. Earnings Flash (LNSR) LENSAR Reports Q2 Revenue $8M